Acute management of acquired brain injury part II: An evidence-based review of pharmacological interventions

References

• Zasler ND, Katz DI, Zafonte RD. Brain injury medicine. Demos Medical Publishing, New York 2007
   Google Scholar
• Teasell R, Bayona N, Marshall S, Cullen N, Bayley M, Chundamala J, Villamere J, Mackie D, Rees L, Hartridge C, et al. A systematic review of the rehabilitation of moderate to severe acquired brain injuries. Brain Injury 2007; 21: 107–112
   PubMed Web of Science ®Google Scholar
• Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database System Reviews 2006; 4: CD003299
   Google Scholar
• ERABI group. Evidence-based review of moderate to severe acquired brain injury. Accessed October 2008 October. Available online at: www.abiebr.com
   Google Scholar
• Moseley AM, Herbert RD, Sherrington C, Maher CG. Evidence for physiotherapy practice: A survey of the Physiotherapy Evidence Database (PEDro). Australian Journal of Physiotherapy 2002; 48: 43–49
   PubMed Web of Science ®Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health 1998; 52: 377–384
   PubMed Web of Science ®Google Scholar
• Adembri C, Venturi L, Pellegrini-Giampietro DE. Neuroprotective effects of propofol in acute cerebral injury. CNS Drug Review 2007; 13: 333–351
   PubMedGoogle Scholar
• Kelly DF, Goodale DB, Williams J, Herr DL, Chappell ET, Rosner MJ, Jacobson J, Levy ML, Croce MA, Maniker AH, et al. Propofol in the treatment of moderate and severe head injury: A randomized, prospective double-blinded pilot trial. Journal of Neurosurgery 1999; 90: 1042–1052
   PubMed Web of Science ®Google Scholar
• Farling PA, Johnston JR, Coppel DL. Propofol infusion for sedation of patients with head injury in intensive care. A preliminary report. Anaesthesia 1989; 44: 222–226
   Google Scholar
• Stewart L, Bullock R, Rafferty C, Fitch W, Teasdale GM. Propofol sedation in severe head injury fails to control high ICP, but reduces brain metabolism. Acta Neurochirgica Supplementum (Wien) 1994; 60: 544–546
   PubMedGoogle Scholar
• Corbett SM, Moore J, Rebuck JA, Rogers FB, Greene CM. Survival of propofol infusion syndrome in a head-injured patient. Critical Care Medicine 2006; 34: 2479–2483
   PubMed Web of Science ®Google Scholar
• Sabsovich I, Rehman Z, Yunen J, Coritsidis G. Propofol infusion syndrome: A case of increasing morbidity with traumatic brain injury. American Journal of Critical Care 2007; 16: 82–85
   PubMed Web of Science ®Google Scholar
• Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357: 117–118
   PubMed Web of Science ®Google Scholar
• Otterspoor LC, Kalkman CJ, Cremer OL. Update on the propofol infusion syndrome in ICU management of patients with head injury. Current Opinion in Anaesthesiology 2008; 21: 544–551
   PubMed Web of Science ®Google Scholar
• Roberts I. Barbiturates for acute traumatic brain injury. Cochrane Database System Reviews 2000; 2: CD000033
   PubMedGoogle Scholar
• Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Practice parameter: Antiepileptic drug treatment of posttraumatic seizures. Archives of Physical Medicine and Rehabilitation 1998; 79: 594–597
   PubMed Web of Science ®Google Scholar
• Rea GL, Rockswold GL. Barbiturate therapy in uncontrolled intracranial hypertension. Neurosurgery 1983; 12: 401–404
   PubMed Web of Science ®Google Scholar
• Rockoff MA, Marshall LF, Shapiro HM. High-dose barbiturate therapy in humans: A clinical review of 60 patients. Annals of Neurology 1979; 6: 194–199
   PubMed Web of Science ®Google Scholar
• Marshall LF, Smith RW, Shapiro HM. The outcome with aggressive treatment in severe head injuries. Part II: Acute and chronic barbiturate administration in the management of head injury. Journal of Neurosurgery 1979; 50: 26–30
   PubMed Web of Science ®Google Scholar
• Llompart-Pou JA, Perez-Barcena J, Raurich JM, Burguera B, Ayestaran JI, Abadal JM, et al. Effect of barbiturate coma on adrenal response in patients with traumatic brain injury. Journal of Endocrinology Investigations 2007; 30: 393–398
   PubMed Web of Science ®Google Scholar
• Stover JF, Stocker R. Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury. European Journal of Clinical Pharmacology 1998; 54: 529–534
   PubMed Web of Science ®Google Scholar
• Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. Journal of Neurosurgery 1988; 69: 15–23
   PubMed Web of Science ®Google Scholar
• Ward JD, Becker DP, Miller JD, Choi SC, Marmarou A, Wood C, Newlon PG, Keenan R. Failure of prophylactic barbiturate coma in the treatment of severe head injury. Journal of Neurosurgery 1985; 62: 383–388
   PubMed Web of Science ®Google Scholar
• Schwartz ML, Tator CH, Rowed DW, Reid SR, Meguro K, Andrews DF. The University of Toronto head injury treatment study: A prospective, randomized comparison of pentobarbital and mannitol. Canadian Journal of Neurological Science 1984; 11: 434–440
   PubMed Web of Science ®Google Scholar
• Perez-Barcena J, Barcelo B, Homar J, Abadal JM, Molina FJ, de la Pena A, Sahuquillo J, Ibanez J. [Comparison of the effectiveness of pentobarbital and thiopental in patients with refractory intracranial hypertension. Preliminary report of 20 patients]. Neurocirugia 2005; 16: 5–12
   PubMedGoogle Scholar
• Nordby HK, Nesbakken R. The effect of high dose barbiturate decompression after severe head injury. A controlled clinical trial. Acta Neurochirgica (Wien) 1984; 72: 157–166
   PubMed Web of Science ®Google Scholar
• Schalen W, Messeter K, Nordstrom CH. Complications and side effects during thiopentone therapy in patients with severe head injuries. Acta Anaesthesiologica Scandinavica 1992; 36: 369–377
   PubMed Web of Science ®Google Scholar
• Metz C, Gobel L, Gruber M, Hoerauf KH, Taeger K. Pharmacokinetics of human cerebral opioid extraction: A comparative study on sufentanil, fentanyl, and alfentanil in a patient after severe head injury. Anesthesiology 2000; 92: 1559–1567
   PubMed Web of Science ®Google Scholar
• de Nadal M, Munar F, Poca MA, Sahuquillo J, Garnacho A, Rossello J. Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: Absence of correlation to cerebral autoregulation. Anesthesiology 2000; 92: 11–19
   PubMed Web of Science ®Google Scholar
• Werner C, Kochs E, Bause H, Hoffman WE, Schulte am EJ. Effects of sufentanil on cerebral hemodynamics and intracranial pressure in patients with brain injury. Anesthesiology 1995; 83: 721–726
   PubMed Web of Science ®Google Scholar
• Marx W, Shah N, Long C, Arbit E, Galicich J, Mascott C, Mallya K, Bedford R. Sufentanil, alfentanil, and fentanyl: Impact on cerebrospinal fluid pressure in patients with brain tumors. Journal of Neurosurgery and Anesthesiology 1989; 1: 3–7
   PubMedGoogle Scholar
• Bunegin L, Albin MS, Ernst PS, Garcia C. Cerebrovascular responses to sufentanil citrate (SC) in primates with and without intracranial hypertension. Journal of Neurosurgery and Anesthesiology 1989; 1: 138–139
   PubMedGoogle Scholar
• Albanese J, Viviand X, Potie F, Rey M, Alliez B, Martin C. Sufentanil, fentanyl, and alfentanil in head trauma patients: A study on cerebral hemodynamics. Critical Care Medicine 1999; 27: 407–411
   PubMed Web of Science ®Google Scholar
• Albanese J, Durbec O, Viviand X, Potie F, Alliez B, Martin C. Sufentanil increases intracranial pressure in patients with head trauma. Anesthesiology 1993; 79: 493–497
   PubMed Web of Science ®Google Scholar
• Sperry RJ, Bailey PL, Reichman MV, Peterson JC, Petersen PB, Pace NL. Fentanyl and sufentanil increase intracranial pressure in head trauma patients. Anesthesiology 1992; 77: 416–420
   PubMed Web of Science ®Google Scholar
• de Nadal M, Munar F, Poca MA, Sahuquillo J, Garnacho A, Rossello J. Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: Absence of correlation to cerebral autoregulation. Anesthesiology 2000; 92: 11–19
   PubMed Web of Science ®Google Scholar
• Engelhard K, Reeker W, Kochs E, Werner C. Effect of remifentanil on intracranial pressure and cerebral blood flow velocity in patients with head trauma. Acta Anaesthesiologica Scandinavica 2004; 48: 396–399
   PubMed Web of Science ®Google Scholar
• Lauer KK, Connolly LA, Schmeling WT. Opioid sedation does not alter intracranial pressure in head injured patients. Canadian Journal of Anaesthesia 1997; 44: 929–933
   PubMed Web of Science ®Google Scholar
• Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S, Schulte AM, Esch J. Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. British Journal of Clinical Pharmacology 1994; 38: 369–372
   PubMed Web of Science ®Google Scholar
• Karabinis A, Mandragos K, Stergiopoulos S, Komnos A, Soukup J, Speelberg B, Kirkham AJ. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: A randomised, controlled trial [ISRCTN50308308]. Critical Care 2004; 8: R268–R280
   Web of Science ®Google Scholar
• McCollam JS, O’Neil MG, Norcross ED, Byrne TK, Reeves ST. Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: A prospective, randomized comparison. Critical Care Medicine 1999; 27: 2454–2458
   PubMedGoogle Scholar
• McClelland M, Woster P, Sweasey T, Hoff JT. Continuous midazolam/atracurium infusions for the management of increased intracranial pressure. Journal of Neuroscience Nursing 1995; 27: 96–101
   PubMedGoogle Scholar
• Davis DP, Kimbro TA, Vilke GM. The use of midazolam for prehospital rapid-sequence intubation may be associated with a dose-related increase in hypotension. Prehospital Emergency Care 2001; 5: 163–168
   PubMedGoogle Scholar
• Sanchez-Izquierdo-Riera JA, Caballero-Cubedo RE, Perez-Vela JL, Ambros-Checa A, Cantalapiedra-Santiago JA, ted-Lopez E. Propofol versus midazolam: Safety and efficacy for sedating the severe trauma patient. Anesthesia and Analgesia 1998; 86: 1219–1224
   PubMed Web of Science ®Google Scholar
• Papazian L, Albanese J, Thirion X, Perrin G, Durbec O, Martin C. Effect of bolus doses of midazolam on intracranial pressure and cerebral perfusion pressure in patients with severe head injury. British Journal of Anaesthesia 1993; 71: 267–271
   PubMed Web of Science ®Google Scholar
• Wakai A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. Cochrane Database System Reviews 2005; 4: CD001049
   PubMedGoogle Scholar
• Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Critical Care Medicine 2005; 33: 196–202
   PubMed Web of Science ®Google Scholar
• Doyle JA, Davis DP, Hoyt DB. The use of hypertonic saline in the treatment of traumatic brain injury. Journal of Trauma 2001; 50: 367–383
   PubMed Web of Science ®Google Scholar
• Task force of the American Association of Neurological Surgeons and Joint Section in Neurotrauma and Critical Care. Guidelines for the management of severe head injury. Brain Trauma Foundation. 1995. Available online at: http://www.guideline.gov/summary/summary.aspx?doc_id=3794&nbr=003020&string=3020
   Google Scholar
• Cruz J, Minoja G, Okuchi K, Facco E. Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: A randomized trial. Journal of Neurosurgery 2004; 100: 376–383
   PubMed Web of Science ®Google Scholar
• Cruz J, Minoja G, Okuchi K. Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: A randomized trial. Neurosurgery 2001; 49: 864–871
   PubMed Web of Science ®Google Scholar
• Cruz J, Minoja G, Okuchi K. Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: A randomized trial. Neurosurgery 2002; 51: 628–637
   PubMed Web of Science ®Google Scholar
• Sorani MD, Morabito D, Rosenthal G, Giacomini KM, Manley GT. Characterizing the dose–response relationship between mannitol and intracranial pressure in traumatic brain injury patients using a high-frequency physiological data collection system. Journal of Neurotrauma 2008; 25: 291–298
   PubMed Web of Science ®Google Scholar
• Bratton SL, Chestnut RM, Ghajar J, Connell Hammond FF, Harris OA, Hartl R, et al. Guidelines for the management of severe traumatic brain injury. XI. Anesthetics, analgesics, and sedatives. Journal of Neurotrauma 2007; 24(Suppl 1)S71–S76
   Google Scholar
• Smith HP, Kelly DL, Jr, McWhorter JM, Armstrong D, Johnson R, Transou C, Howard G. Comparison of mannitol regimens in patients with severe head injury undergoing intracranial monitoring. Journal of Neurosurgery 1986; 65: 820–824
   PubMed Web of Science ®Google Scholar
• Hartl R, Bardt TF, Kiening KL, Sarrafzadeh AS, Schneider GH, Unterberg AW. Mannitol decreases ICP but does not improve brain-tissue pO2 in severely head-injured patients with intracranial hypertension. Acta Neurochirgica Supplementum 1997; 70: 40–42
   PubMedGoogle Scholar
• Vialet R, Albanese J, Thomachot L, Antonini F, Bourgouin A, Alliez B, Martin C. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Critical Care Medicine 2003; 31: 1683–1687
   PubMed Web of Science ®Google Scholar
• Ware ML, Nemani VM, Meeker M, Lee C, Morabito DJ, Manley GT. Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: A preliminary study. Neurosurgery 2005; 57: 727–736
   PubMed Web of Science ®Google Scholar
• Francony G, Fauvage B, Falcon D, Canet C, Dilou H, Lavagne P, Jacquot C, Payen JF. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine 2008; 36: 795–800
   PubMed Web of Science ®Google Scholar
• Sayre MR, Daily SW, Stern SA, Storer DL, van Loveren HR, Hurst JM. Out-of-hospital administration of mannitol to head-injured patients does not change systolic blood pressure. Acadamy of Emergency Medicine 1996; 3: 840–848
   PubMed Web of Science ®Google Scholar
• Horn P, Munch E, Vajkoczy P, Herrmann P, Quintel M, Schilling L, Schmiedek P, Schurer L. Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. Neurology Research 1999; 21: 758–764
   PubMed Web of Science ®Google Scholar
• Khanna S, Davis D, Peterson B, Fisher B, Tung H, O’Quigley J, Deutsch R. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Critical Care Medicine 2000; 28: 1144–1151
   PubMed Web of Science ®Google Scholar
• Suarez JI. Hypertonic saline for cerebral edema and elevated intracranial pressure. Cleveland Clinic Journal of Medicine 2004; 71(Suppl 1)S9–S13
   Google Scholar
• Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE. Hypertonic saline resuscitation of patients with head injury: A prospective, randomized clinical trial. Journal of Trauma 1998; 44: 50–8
   PubMedGoogle Scholar
• Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, Kai Lo S. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. New England Journal of Medicine 2007; 357: 874–884
   PubMed Web of Science ®Google Scholar
• Cooper DJ, Myles PS, McDermott FT, Murray LJ, Laidlaw J, Cooper G, Tremayne AB, Bernard SS, Ponsford J. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: A randomized controlled trial. Journal of the American Medical Association 2004; 291: 1350–1357
   PubMed Web of Science ®Google Scholar
• Simma B, Burger R, Falk M, Sacher P, Fanconi S. A prospective, randomized, and controlled study of fluid management in children with severe head injury: Lactated Ringer's solution versus hypertonic saline. Critical Care Medicine 1998; 26: 1265–1270
   PubMed Web of Science ®Google Scholar
• Lescot T, Degos V, Zouaoui A, Preteux F, Coriat P, Puybasset L. Opposed effects of hypertonic saline on contusions and noncontused brain tissue in patients with severe traumatic brain injury. Critical Care Medicine 2006; 34: 3029–3033
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suarez JI, Bhardwaj A, Mirski M, Schnitzer MS, Hanley DF, Ulatowski JA. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. Critical Care Medicine 1998; 26: 440–446
   PubMed Web of Science ®Google Scholar
• Schatzmann C, Heissler HE, Konig K, Klinge-Xhemajli P, Rickels E, Muhling M, Borschel M, Samii M. Treatment of elevated intracranial pressure by infusions of 10% saline in severely head injured patients. Acta Neurochirgica Supplementum 1998; 71: 31–33
   PubMedGoogle Scholar
• Pascual JL, Maloney-Wilensky E, Reilly PM, Sicoutris C, Keutmann MK, Stein SC, LeRoux PD, Gracias VH. Resuscitation of hypotensive head-injured patients: Is hypertonic saline the answer?. American Surgery 2008; 74: 253–259
   PubMed Web of Science ®Google Scholar
• Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database System Reviews 2005; 1: CD000196
   Google Scholar
• Grumme T, Baethmann A, Kolodziejczyk D, Krimmer J, Fischer M, von Eisenhart RB, Rothe B, Pelka R, Bennefled H, Pollauer E. Treatment of patients with severe head injury by triamcinolone: A prospective, controlled multicenter clinical trial of 396 cases. Research in Experimental Medicine (Berlin) 1995; 195: 217–229
   PubMedGoogle Scholar
• Cooper PR, Moody S, Clark WK, Kirkpatrick J, Maravilla K, Gould AL, Drane W. Dexamethasone and severe head injury. A prospective double-blind study. Journal of Neurosurgery 1979; 51: 307–316
   PubMed Web of Science ®Google Scholar
• Saul TG, Ducker TB, Salcman M, Carro E. Steroids in severe head injury: A prospective randomized clinical trial. Journal of Neurosurgery 1981; 54: 596–600
   PubMed Web of Science ®Google Scholar
• Giannotta SL, Weiss MH, Apuzzo ML, Martin E. High dose glucocorticoids in the management of severe head injury. Neurosurgery 1984; 15: 497–501
   PubMed Web of Science ®Google Scholar
• Dearden NM, Gibson JS, McDowall DG, Gibson RM, Cameron MM. Effect of high-dose dexamethasone on outcome from severe head injury. Journal of Neurosurgery 1986; 64: 81–88
   PubMed Web of Science ®Google Scholar
• Braakman R, Schouten HJ, Blaauw-van DM, Minderhoud JM. Megadose steroids in severe head injury. Results of a prospective double-blind clinical trial. Journal of Neurosurgery 1983; 58: 326–330
   Google Scholar
• Kaktis JV, Pitts LH. Complications associated with use of megadose corticosteroids in head-injured adults. Journal of Neurosurgery Nursing 1980; 12: 166–171
   PubMedGoogle Scholar
• Watson NF, Barber JK, Doherty MJ, Miller JW, Temkin NR. Does glucocorticoid administration prevent late seizures after head injury?. Epilepsia 2004; 45: 690–694
   PubMed Web of Science ®Google Scholar
• Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Research Review 2008; 57: 386–397
   PubMed Web of Science ®Google Scholar
• Vagnerova K, Koerner IP, Hurn PD. Gender and the injured brain. Anesthesia and Analgesia 2008; 107: 201–214
   PubMed Web of Science ®Google Scholar
• Marmarou A, Nichols J, Burgess J, Newell D, Troha J, Burnham D, Pitts L. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: Results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. Journal of Neurotrauma 1999; 16: 431–444
   Google Scholar
• Narotam PK, Rodell TC, Nadvi SS, Bhoola KD, Troha JM, Parbhoosingh R, van Dellen JR. Traumatic brain contusions: A clinical role for the kinin antagonist CP-0127. Acta Neurochirgica (Wien) 1998; 140: 793–802
   PubMed Web of Science ®Google Scholar
• Francel PC. Bradykinin and neuronal injury. Journal of Neurotrauma 1992; 9(Suppl 1)S27–S45
   Google Scholar
• Hellal F, Pruneau D, Palmier B, Faye P, Croci N, Plotkine M, Marchand Verrecchiac. Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. Journal of Neurotrauma 2003; 20: 841–851
   PubMed Web of Science ®Google Scholar
• Marmarou A, Guy M, Murphey L, Roy F, Layani L, Combal JP, Marquer C. A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. Journal of Neurotrauma 2005; 22: 1444–1455
   PubMed Web of Science ®Google Scholar
• Kulah A, Akar M, Baykut L. Dimethyl sulfoxide in the management of patient with brain swelling and increased intracranial pressure after severe closed head injury. Neurochirurgia (Stuttgart) 1990; 33: 177–180
   PubMedGoogle Scholar
• Marshall LF, Camp PE, Bowers SA. Dimethyl sulfoxide for the treatment of intracranial hypertension: A preliminary trial. Neurosurgery 1984; 14: 659–663
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, Consroe P. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia 1988; 44: 762–764
   PubMedGoogle Scholar
• Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sakolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proceedings of the National Academy of Sciences (USA) 1989; 86: 9584–9587
   PubMed Web of Science ®Google Scholar
• Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. European Journal of Pharmacology 1995; 283: 19–29
   PubMed Web of Science ®Google Scholar
• Shohami E, Novikov M, Bass R. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Research 1995; 674: 55–62
   PubMed Web of Science ®Google Scholar
• Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Critical Care Medicine 2002; 30: 548–554
   PubMed Web of Science ®Google Scholar
• Maas AI, Murray G, Henney H, III, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N. Efficacy and safety of dexanabinol in severe traumatic brain injury: Results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurology 2006; 5: 38–45
   PubMed Web of Science ®Google Scholar
• Fried RC, Dickerson RN, Guenter PA, Stein TP, Gennarelli TA, Dempsey DT, Buzby GP, Mullen JL. Barbiturate therapy reduces nitrogen excretion in acute head injury. Journal of Trauma 1989; 29: 1558–1564
   PubMedGoogle Scholar
• Thorat JD, Wang EC, Lee KK, Seow WT, Ng I. Barbiturate therapy for patients with refractory intracranial hypertension following severe traumatic brain injury: Its effects on tissue oxygenation, brain temperature and autoregulation. Journal of Clinical Neuroscience 2008; 15: 143–148
   PubMed Web of Science ®Google Scholar
• Schalen W, Sonesson B, Messeter K, Nordstrom G, Nordstrom CH. Clinical outcome and cognitive impairment in patients with severe head injuries treated with barbiturate coma. Acta Neurochirgica (Wien) 1992; 117: 153–159
   PubMed Web of Science ®Google Scholar
• Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svaboda P, Brayley N, Mazairac G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet 2004; 364: 1321–1328
   PubMed Web of Science ®Google Scholar
• Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine 2007; 49: 391–402
   PubMed Web of Science ®Google Scholar
• Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Critical Care 2008; 12: R61
   PubMed Web of Science ®Google Scholar
• Karaca M, Bilgin UY, Akar M, de la Torre JC. Dimethly sulphoxide lowers ICP after closed head trauma. European Journal of Clinical Pharmacology 1991; 40: 113–114
   PubMed Web of Science ®Google Scholar